Kevin Warshs Potential Fed Leadership Could Reshape Market Intervention Framework Trump Urges Bank of America and JPMorgan to End Alleged Discrimination Against Conservative Clients Barclays Increases Energy Transfer Price Target Citing Undervaluation Morgan Stanley Highlights Potential Turnaround for Franklin Resources BEN Rising Gas Prices Weigh on Consumer Spending Retail Sales Growth Slows Economy and Welfare Alan Milburn Criticizes Imbalance in Youth Spending Calls for Reform Prosperity Bancshares PB Q1 2026 Earnings EPS Misses Estimates Stock Slides AHG Q1 2020 Earnings EPS Misses Estimates Amid Lack of Revenue Disclosure Stock Declines 563 iQIYI Q1 2026 Earnings EPS Misses Estimates as Stock Declines 182 Cavco Industries Q1 2026 Earnings EPS Beat Drives Positive Stock Reaction CBOE Q1 2026 Earnings EPS Surge Drives Shares Higher BJ Q1 2026 Earnings EPS Beat Fails to Lift Stock Aldel Financial II Inc Warrants ALDFW Plunge 2174 Key Levels to Watch Astrotech Corporation ASTC Surges Over 450 in Historic Rally on Key Corporate Development Colony Bankcorp CBAN Holds Near Resistance as Volume Fades Western Asset Managed Municipals Fund MMU Holds Near Support Amid Modest Decline Six Flags Entertainment FUN Edges Higher as Stock Nears Key Resistance Zone Oil Prices Slide as US Signals Iran Deal and Hormuz Reopening May Be Imminent SRAD Q1 2026 Earnings EPS Misses Estimates as Stock Rises Modestly Ituran ITRN Rallies to 5929 Key Resistance Level in Focus LITS Q4 2024 Earnings Significant EPS Miss Raises Concerns Amid Lack of Revenue Disclosure Piper Sandler Companies PIPR Q1 2026 Earnings Earnings Beat Estimates Stock Edges Higher NWE Q1 2026 Earnings EPS Beats Estimates by 691 as Utility Operations Show Stability STTK Q1 2026 Earnings Shattuck Labs Reports Narrower Loss Beats EPS Estimates BLDP Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Investor Sentiment Iron Mountain IRM Q1 2026 Earnings EPS Surpasses Estimates by 153 Stock Edges Lower Firefly Neuroscience Inc AIFF Q3 1998 Earnings Steep Earnings Miss as PreRevenue Biotech Faces Cash Burn Headwinds